Bioniche's Urocidin filing delayed six months
This article was originally published in Scrip
Executive Summary
Ontario, Canada-based Bioniche Life Sciences has had to delay the first filing of its bladder cancer product Urocidin by six months, after discussions with Health Canada revealed that the regulator's requests for more information would take longer to fulfil than anticipated.